BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-01
182 industry Phase 2/3 trial readout(s) and 20 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-01 est. | P3 | Aesculap Biologics, LLC | NCT03219307 NOVOCART 3D Treatment Following Microfracture Failure | Articular Cartilage Defect | active not recruiting | 30 |
| 2026-01 est. | P3 | Wockhardt | NCT03630081 Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) | Complicated Urinary Tract Infection; Acute Pyelonephritis | unknown | 1004 |
| 2026-01 est. | P1/P2 | Immunity Pharma Ltd. | NCT03652805 A Study of IPL344 in the Treatment of ALS Patients | Amyotrophic Lateral Sclerosis | suspended | 15 |
| 2026-01 est. | P1/P2 | 4D Molecular Therapeutics FDMT | NCT04519749 An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease | Fabry Disease | active not recruiting | 18 |
| 2026-01 est. | P1/P2 | Treadwell Therapeutics, Inc | NCT04730258 A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML | Acute Myeloid Leukemia; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; AML; MDS; CMML | active not recruiting | 72 |
| 2026-01 est. | P1/P2 | Azitra Inc. AZTR | NCT04731259 Study to Evaluate the Safety of ATR-04 | Epidermal Growth Factor; Papulopustular Rosacea | withdrawn | |
| 2026-01 est. | P2 | ASC Therapeutics | NCT04883918 ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) | Acute-graft-versus-host Disease | unknown | 60 |
| 2026-01 est. | P3 | Inmunotek S.L. | NCT04891237 Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen | Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergic | recruiting | 180 |
| 2026-01 est. | P1/P2 | Immunitas Therapeutics | NCT05565417 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Triple Negative Breast Cancer; Cu | active not recruiting | 67 |
| 2026-01 est. | P3 | R-Pharm International, LLC | NCT05673902 Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis | Idiopathic Recurrent Pericarditis | active not recruiting | 17 |
| 2026-01 est. | P3 | Theravance Biopharma | NCT05696717 Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension; MSA - Multiple System Atrophy | active not recruiting | 102 |
| 2026-01 est. | P1/P2 | Traws Pharma, Inc. TRAW | NCT05705505 Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies | Endometrioid Endometrial Cancer | unknown | 60 |
| 2026-01 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05901935 DP303c in Patients With HER2-positive Advanced Breast Cancer | HER2-positive Advanced Breast Cancer | not yet recruiting | 420 |
| 2026-01 est. | P2 | AnaptysBio, Inc. ANAB | NCT06127043 A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA) | Ulcerative Colitis | active not recruiting | 132 |
| 2026-01 est. | P2 | Akeso | NCT06196203 A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Higher-risk Myelodysplastic Syndromes | recruiting | 90 |
| 2026-01 est. | P1/P2 | Dong-A ST Co., Ltd. | NCT06293651 Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembro | Locally Advanced or Metastatic Solid Tumors | recruiting | 125 |
| 2026-01 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06391710 HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction | Heart Failure With Preserved Ejection Fraction | active not recruiting | 203 |
| 2026-01 est. | P2 | Hope Biosciences Research Foundation | NCT06623240 HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis (JIA) | withdrawn | |
| 2026-01 est. | P3 | CanSino Biologics Inc. | NCT06857370 Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine | Diphtheria, Tetanus and Acellular Pertussis | active not recruiting | 780 |
| 2026-01 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07070349 A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | Patients With Solid Tumors | recruiting | 48 |
| 2026-01 est. | P2 | Guangzhou Patronus Biotech Co., Ltd. | NCT07311148 A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 40 Years and Older | Herpes Zoster (HZ); Shingles; VZV; Recombinant Zoster Vaccine | active not recruiting | 840 |
| 2026-01-01 est. | P1/P2 | ENB Therapeutics, Inc | NCT04205227 ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Cancer; Melanoma; Ovary Cancer; Pancreatic Cancer; Solid Tumor | unknown | 137 |
| 2026-01-01 est. | P1/P2 | Rapa Therapeutics LLC | NCT05144698 RAPA-201 Therapy of Solid Tumors | Solid Tumor; Small Cell and Non-small Cell Lung Cancer; Head and Neck Cancer; Squamous Cell Carcinom | recruiting | 37 |
| 2026-01-01 est. | P1/P2 | Ashvattha Therapeutics, Inc. | NCT05395624 Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers | Amyotrophic Lateral Sclerosis (ALS); Parkinson Disease (PD); Alzheimer Disease (AD); Multiple Sclero | recruiting | 65 |
| 2026-01-01 est. | P2 | HEM Pharma Inc. | NCT05527301 HEM1036 Phase 2 Study in Low Anterior Resection Syndrome | LARS - Low Anterior Resection Syndrome | unknown | 67 |
| 2026-01-01 est. | P3 | ONY | NCT05960929 InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS | Respiratory Distress Syndrome (Neonatal); Intubation Complication; Death; Neonatal | recruiting | 220 |
| 2026-01-01 est. | P1/P2 | Cellcolabs Clinical LTD. | NCT06070532 A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty | Frailty | not yet recruiting | 12 |
| 2026-01-01 est. | P2 | MedRegen LLC | NCT06315608 MRG-001 in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis; Lou Gehrig Disease; Motor Neuron Disease; Motor Neuron Atrophy | unknown | 10 |
| 2026-01-01 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06703177 A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors | Advanced Solid Tumors | recruiting | 876 |
| 2026-01-01 est. | P2 | Oragenics, Inc. OGEN | NCT06870240 A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Ad | Mild Traumatic Brain Injury, Concussion | not yet recruiting | 40 |
| 2026-01-02 | P2 | Lipomedix Pharmaceuticals Inc. | NCT06478862 Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy | Cancer of Ovary; Pancreatic Ductal Adenocarcinoma | terminated | 19 |
| 2026-01-02 | P2 | Alume Biosciences, Inc. | NCT06662097 A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery | Surgery; Nerve Injury; Imaging | completed | 27 |
| 2026-01-02 | P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT07550387 A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia | SCHIZOPHRENIA 1 (Disorder) | completed | 363 |
| 2026-01-04 | P3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT06839664 A Study of HS-20094 in Chinese Adults With Overweight or Obesity | Overweight; Obesity | completed | 604 |
| 2026-01-05 | P2 | Cartesian Therapeutics RNAC | NCT04146051 Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | Myasthenia Gravis, Generalized | active not recruiting | 30 |
| 2026-01-05 | P2 | Agenus Inc. AGEN | NCT05630183 A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | completed | 81 |
| 2026-01-05 | P2 | Teva Branded Pharmaceutical Products R&D LLC | NCT05668013 A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | Crohn Disease; Colitis, Ulcerative | active not recruiting | 247 |
| 2026-01-05 | P3 | Alexion Pharmaceuticals, Inc. | NCT06291376 Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | Immunoglobulin A Nephropathy; IgAN | active not recruiting | 584 |
| 2026-01-05 est. | P3 | AbbVie ABBV | NCT06390722 A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis; Sleep Disturbance | withdrawn | |
| 2026-01-06 | P2 | Amgen AMGN | NCT06054113 Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) | B Precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory B Precursor Acute Lymphoblastic Leukem | active not recruiting | 18 |
| 2026-01-06 | P3 | Alexion Pharmaceuticals, Inc. | NCT06079359 Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP | Hypophosphatasia | active not recruiting | 30 |
| 2026-01-06 | P3 | Chengdu Suncadia Medicine Co., Ltd. | NCT06715943 Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment | Paroxysmal Nocturnal Hemoglobinuria | completed | 39 |
| 2026-01-07 | P3 | Delta-Fly Pharma, Inc. | NCT03926624 Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | Leukemia, Myeloid, Acute | terminated | 167 |
| 2026-01-07 | P2 | Pharmicell Co., Ltd. | NCT04594850 Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously | Erectile Dysfunction | completed | 54 |
| 2026-01-07 | P2 | AstraZeneca AZN | NCT05251259 Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma | Asthma | completed | 670 |
| 2026-01-07 | P3 | Pfizer PFE | NCT05477524 An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) | Lyme Disease | completed | 12546 |
| 2026-01-07 | P2 | Eli Lilly and Company LLY | NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity; Overweight | completed | 288 |
| 2026-01-07 | P2 | Latigo Biotherapeutics LTGO | NCT07102459 An Efficacy and Safety Study of LTG-001 Following Abdominoplasty | Acute Pain; Postoperative Pain Control | completed | 343 |
| 2026-01-07 est. | P2 | Suzhou Abogen Biosciences Co., Ltd. | NCT07289542 Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above | Respiratory Syncytial Virus | active not recruiting | 420 |
| 2026-01-08 | P2 | Innate Pharma IPHA | NCT03902184 IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma | Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides/Sezary Syndrome | completed | 170 |
| 2026-01-08 | P2 | Eli Lilly and Company LLY | NCT06037252 A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity | Type 2 Diabetes; Obesity | active not recruiting | 414 |
| 2026-01-08 | P3 | Hanmi Pharmaceutical Company Limited HAFC | NCT06174766 A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients | Hypertension | completed | 356 |
| 2026-01-08 | P3 | Eli Lilly and Company LLY | NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Psoriasis; Obesity | completed | 281 |
| 2026-01-08 | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06841445 Efficacy and Safety of HRS9531 Tablet in Obese Subjects | Chronic Management of Body Weight | completed | 166 |
| 2026-01-08 | P2 | Halia Therapeutics, Inc. | NCT07052006 A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia | Myelodysplastic Syndrome; Anemia in Myelodysplastic Syndromes | completed | 37 |
| 2026-01-09 | P2 | BeiGene | NCT04116437 Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphom | completed | 96 |
| 2026-01-10 | P3 | RDC Clinical Pty Ltd | NCT06827327 LC-Plasma for Preventing URTIs and Reducing Symptoms | Healthy Volunteer; URTI | completed | 637 |
| 2026-01-12 | P3 | Chiesi Farmaceutici S.p.A. | NCT04320342 A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With | COPD; COPD Exacerbation | completed | 3406 |
| 2026-01-12 | P3 | Eli Lilly and Company LLY | NCT04819100 A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) | Carcinoma, Non-Small-Cell Lung | active not recruiting | 152 |
| 2026-01-12 | P3 | Janssen Research & Development, LLC | NCT05083182 A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis | Arthritis, Juvenile | completed | 48 |
| 2026-01-12 | P2 | Idorsia Pharmaceuticals Ltd. | NCT05423717 Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder | Insomnia | completed | 166 |
| 2026-01-12 | P3 | Xenon Pharmaceuticals Inc. XENE | NCT05614063 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures | Focal Onset Seizures | completed | 380 |
| 2026-01-12 | P3 | Soleno Therapeutics, Inc. | NCT05701774 Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | completed | 77 |
| 2026-01-12 | P2 | Genentech, Inc. | NCT05785624 A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associa | Idiopathic Pulmonary Fibrosis; Systemic Sclerosis With Lung Involvement | terminated | 286 |
| 2026-01-12 | P2 | AstraZeneca AZN | NCT05925530 Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resect | Non-small Cell Lung Cancer | active not recruiting | 142 |
| 2026-01-12 | P2 | Pfizer PFE | NCT06105632 A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Br | Advanced or Metastatic Breast Cancer | active not recruiting | 333 |
| 2026-01-12 est. | P2 | EMD Serono Research & Development Institute, Inc. | NCT06424717 Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) | Urothelial Carcinoma | withdrawn | |
| 2026-01-12 | P3 | argenx ARGX | NCT06558279 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | Myasthenia Gravis, Ocular | active not recruiting | 141 |
| 2026-01-12 | P2 | Eli Lilly and Company LLY | NCT06568042 Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy | Neuropathic Pain; Distal Sensory Polyneuropathy | completed | 558 |
| 2026-01-12 | P2 | Thiogenesis Therapeutics, Inc. TTIPF | NCT06644534 A Study to Assess TTI-0102 vs Placebo in MELAS Patients | MELAS Syndrome; Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS) | completed | 9 |
| 2026-01-12 | P2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | NCT06703021 A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity | Obesity; Overweight; Chronic Weight Management | completed | 85 |
| 2026-01-12 | P2 | Kardigan, Inc. KARD | NCT06864104 A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) | Hypertension | completed | 206 |
| 2026-01-12 | P3 | Sanofi SNY | NCT07079670 Safety and Immunogenicity of NVX-CoV2705 | COVID-19; SARS-CoV-2 Infection | completed | 676 |
| 2026-01-13 | P1/P2 | Taiho Oncology, Inc. | NCT03502668 Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS | Myelodysplastic Syndromes | completed | 160 |
| 2026-01-13 | P3 | Octapharma | NCT04867837 Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor | Acute Major Bleeding | terminated | 100 |
| 2026-01-13 | P2 | Barinthus Biotherapeutics | NCT05343481 Efficacy of VTP-300 in Chronic Hepatitis B Infection | Chronic Hepatitis B | completed | 121 |
| 2026-01-13 | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06382142 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PA | Triple-Negative Breast Cancer | active not recruiting | 418 |
| 2026-01-13 | P1/P2 | GlaxoSmithKline | NCT06382311 A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger | Influenza, Human | completed | 991 |
| 2026-01-13 | P2 | Boehringer Ingelheim | NCT06675929 A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH | Compensated Liver Cirrhosis; Metabolic Dysfunction Associated Steatohepatitis (MASH) | completed | 28 |
| 2026-01-14 | P3 | Merck Sharp & Dohme LLC MRK | NCT02684292 Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) | Hodgkin Lymphoma | completed | 304 |
| 2026-01-14 | P2 | GlaxoSmithKline | NCT04494412 An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection | Influenza, Human; Arthralgia | completed | 8 |
| 2026-01-14 | P3 | Eli Lilly and Company LLY | NCT05559359 A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis; Eczema | active not recruiting | 377 |
| 2026-01-14 | P3 | Palvella Therapeutics, Inc. PVLA | NCT06239480 SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | Microcystic Lymphatic Malformation | active not recruiting | 51 |
| 2026-01-14 | P3 | Shanghai Hutchison Pharmaceuticals Limited | NCT06377072 Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy | Cervical Spondylotic Myelopathy | completed | 428 |
| 2026-01-14 | P2 | BioTheraVision, Inc. | NCT06543303 Evaluation of BTV100 in Subjects With Dry Eye Disease | Dry Eye | completed | 123 |
| 2026-01-14 | P2 | Kissei Pharmaceutical Co., Ltd. | NCT06722729 A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease | Parkinson Disease | completed | 178 |
| 2026-01-14 | P2 | BrightGene Bio-Medical Technology Co., Ltd. | NCT06911203 A Study of BGM0504 in Participants With Obesity | Obesity | completed | 96 |
| 2026-01-15 | P2 | Celgene | NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | Multiple Myeloma | completed | 312 |
| 2026-01-15 est. | P2/P3 | Laminar Pharmaceuticals | NCT04250922 LAM561 With RT and TMZ for Adults With Glioblastoma | Primary Glioblastoma; Glioblastoma Multiforme | active not recruiting | 144 |
| 2026-01-15 | P3 | Orchard Therapeutics | NCT04283227 OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD) | Lysosomal Storage Diseases; Metachromatic Leukodystrophy | active not recruiting | 6 |
| 2026-01-15 | P3 | Immedica Pharma AB | NCT05299554 Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia | completed | 76 |
| 2026-01-15 | P1/P2 | TCRCure Biopharma Ltd. | NCT05357027 HPV16 E6 TCR T Cells for Cervical Carcinoma | Cervical Carcinoma | terminated | 5 |
| 2026-01-15 | P3 | Hangzhou Highlightll Pharmaceutical Co., Ltd | NCT06020144 A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs | Rheumatoid Arthritis | completed | 459 |
| 2026-01-15 | P3 | KalVista Pharmaceuticals, Ltd. | NCT06467084 Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II | Hereditary Angioedema | completed | 36 |
| 2026-01-15 | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06837896 Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer | Prostate Cancer | completed | 111 |
| 2026-01-15 est. | P2 | Sinovac Biotech Co., Ltd SVA | NCT07055880 Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell) | Rabies | not yet recruiting | 120 |
| 2026-01-15 | P3 | Yuhan Corporation | NCT07111468 Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis | Acute Bronchitis | completed | 286 |
| 2026-01-16 | P2/P3 | Bristol-Myers Squibb BMY | NCT03723655 A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM | Hypertrophic Cardiomyopathy; Obstructive Hypertrophic Cardiomyopathy; Non-obstructive Hypertrophic C | completed | 314 |
| 2026-01-16 | P3 | Mirati Therapeutics Inc. | NCT04793958 Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | Advanced Colorectal Cancer; Metastatic Colorectal Cancer | active not recruiting | 461 |
| 2026-01-16 | P3 | Dizal Pharmaceuticals | NCT05668988 A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) | Non-small Cell Lung Cancer | active not recruiting | 324 |
| 2026-01-16 est. | P2 | Loxo Oncology, Inc. | NCT06104683 A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis; Multiple Sclerosis | withdrawn | |
| 2026-01-16 | P2 | H. Lundbeck A/S | NCT06323928 A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments | Migraine | completed | 874 |
| 2026-01-16 | P2 | Eli Lilly and Company LLY | NCT06643728 A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight | Obesity; Overweight | completed | 252 |
| 2026-01-16 | P3 | Lipocine Inc. LPCN | NCT06979544 A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD | Depression, Postpartum; Depression, Post-Partum; Postpartum Depression (PPD); Post-Natal Depression; | completed | 90 |
| 2026-01-16 | P3 | Nanjing Zenshine Pharmaceuticals | NCT07095257 Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza | Respiratory Viral Infection | completed | 169 |
| 2026-01-17 | P3 | Guangdong Raynovent Biotech Co., Ltd | NCT07229807 Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A | Influenza a | completed | 120 |
| 2026-01-19 | P2 | ModernaTX, Inc. | NCT04975893 A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | Cytomegalovirus Infection | completed | 135 |
| 2026-01-19 | P3 | AstraZeneca AZN | NCT05158387 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. | Chronic Obstructive Pulmonary Disease (COPD) | completed | 1172 |
| 2026-01-19 | P3 | AstraZeneca AZN | NCT05166889 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations | Chronic Obstructive Pulmonary Disease (COPD) | completed | 1132 |
| 2026-01-19 est. | P2 | Mankind Pharma Limited | NCT07098663 Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes | Type 2 Diabetes Mellitus (T2DM); Food Effect; Safety and Tolerability; Obesity | recruiting | 68 |
| 2026-01-20 | P3 | IBSA Institut Biochimique SA | NCT04549116 Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer. | Infertility | completed | 688 |
| 2026-01-20 | P3 | AVEO Pharmaceuticals, Inc. | NCT04987203 Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | Renal Cell Carcinoma | completed | 343 |
| 2026-01-20 | P2/P3 | Takeda TAK | NCT05755035 A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases | Primary Immunodeficiency Diseases (PID) | completed | 65 |
| 2026-01-20 | P3 | Eli Lilly and Company LLY | NCT06047548 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Overweight; Obesity | completed | 441 |
| 2026-01-20 est. | P2 | Xizang Haisco Pharmaceutical Co., Ltd | NCT06996912 A Study for HSK44459 in Participants With Atopic Dermatitis | Atopic Dermatitis (AD) | active not recruiting | 150 |
| 2026-01-20 | P3 | Sanofi SNY | NCT07002060 Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults | Yellow Fever Immunization | completed | 640 |
| 2026-01-20 | P2 | EMS | NCT07843056 A Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia. | Schizophenia Disorder | completed | 121 |
| 2026-01-21 | P3 | Merck Sharp & Dohme LLC MRK | NCT04210115 Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYN | Esophageal Squamous Cell Carcinoma (ESCC); Gastroesophageal Junction Carcinoma (GEJC); Esophageal Ad | completed | 703 |
| 2026-01-21 | P2 | Afimmune | NCT05861453 Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease | Sickle Cell Disease | completed | 35 |
| 2026-01-21 | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT05891483 Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | completed | 114 |
| 2026-01-21 | P3 | Dongkook Pharmaceutical Co., Ltd. | NCT06490328 Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer | Advanced Prostate Cancer | completed | 161 |
| 2026-01-21 | P2 | Indivior Inc. | NCT06576843 INDV-6001 Multiple-Dose Pharmacokinetic Study | Moderate to Severe Opioid Use Disorder | completed | 123 |
| 2026-01-21 | P3 | Sun Pharmaceutical Industries Limited | NCT06611163 A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. | Moderate to Severe Genital Psoriasis | active not recruiting | 206 |
| 2026-01-21 | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06650007 the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone | Diabetes Mellitus, Type 2 | completed | 218 |
| 2026-01-21 | P2 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT06978699 A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | PNH - Paroxysmal Nocturnal Hemoglobinuria | completed | 26 |
| 2026-01-22 | P3 | AstraZeneca AZN | NCT06067828 A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI | Chronic Obstructive Pulmonary Disease | completed | 171 |
| 2026-01-22 | P3 | Eli Lilly and Company LLY | NCT06354660 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T | Diabetes Type 2 | completed | 537 |
| 2026-01-22 | P2 | InflaRx GmbH IFRX | NCT06555328 Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa | Chronic Urticaria, Idiopathic; Hidradenitis; Hidradenitis Suppurativa | terminated | 73 |
| 2026-01-23 | P3 | Seagen, a wholly owned subsidiary of Pfizer | NCT04404283 Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | Diffuse Large B-cell Lymphoma | active not recruiting | 240 |
| 2026-01-23 | P3 | ViiV Healthcare | NCT05911360 A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Imm | HIV; HIV Infections | completed | 205 |
| 2026-01-23 | P3 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | NCT06258148 A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | completed | 465 |
| 2026-01-23 | P3 | Sandoz | NCT06587451 Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® | Melanoma | terminated | 52 |
| 2026-01-23 | P2 | Prelude Therapeutics Incorporated PRLD | NCT06682806 A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | Advanced Solid Tumor; Esophageal Cancer; Metastatic Solid Tumor; Non-small Cell Lung Cancers; SMARCA | terminated | 6 |
| 2026-01-23 | P1/P2 | Genenta Science SAEN | NCT06716853 A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Ca | Clear Cell RCC | terminated | 10 |
| 2026-01-23 | P2 | Halia Therapeutics, Inc. | NCT07172867 A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM | Diabetes Mellitus, Type 2; Obesity | withdrawn | |
| 2026-01-25 est. | P1/P2 | Innolake Biopharm | NCT05955105 A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | Head and Neck Cancer; Cervical Cancer; Endometrial Cancer; Triple Negative Breast Cancer; Ovarian Ca | unknown | 200 |
| 2026-01-26 | P3 | Merck Sharp & Dohme LLC MRK | NCT03924856 Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-inv | Bladder Cancer | completed | 907 |
| 2026-01-26 | P2 | AbbVie ABBV | NCT04295538 Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acu | Spinal Cord Injury (SCI) | completed | 60 |
| 2026-01-26 | P2 | OncoSil Medical Limited | NCT05466799 FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Cancer | active not recruiting | 88 |
| 2026-01-26 | P3 | Cassiopea SpA | NCT05910450 A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss | Alopecia, Androgenetic | completed | 703 |
| 2026-01-26 | P2 | Shanghai SIMR Biotechnology Co., Ltd. | NCT06571448 Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia | Trigeminal Neuralgia | completed | 138 |
| 2026-01-26 | P3 | Livzon Pharmaceutical Group Inc. | NCT07746479 A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis ) | Psoriasis | completed | 244 |
| 2026-01-27 | P3 | Hoffmann-La Roche | NCT04586010 A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | active not recruiting | 746 |
| 2026-01-27 | P2 | Ono Pharmaceutical Co., Ltd. | NCT04947319 Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) | Refractory Primary Central Nervous System Lymphoma; Primary CNS Lymphoma | active not recruiting | 119 |
| 2026-01-27 est. | P1/P2 | Tallac Therapeutics | NCT05399654 A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | unknown | 72 |
| 2026-01-28 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT03598608 Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (M | Hodgkin Disease; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell | terminated | 137 |
| 2026-01-28 | P1/P2 | Amgen AMGN | NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | Solid Tumors | terminated | 260 |
| 2026-01-28 est. | P3 | Akeso | NCT05489289 A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | Hepatocellular Carcinoma | recruiting | 570 |
| 2026-01-28 | P3 | Novartis Pharmaceuticals NVS | NCT06869785 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | Relapsing Multiple Sclerosis (RMS) | active not recruiting | 196 |
| 2026-01-28 | P2 | Graviton Bioscience Corporation | NCT06979505 GV101 in Healthy Obese Participants | Weight Management | completed | 131 |
| 2026-01-28 | P1/P2 | AstraZeneca AZN | NCT07128615 A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) | Influenza A | active not recruiting | 405 |
| 2026-01-28 | P3 | Colgate Palmolive CL | NCT07224828 The Efficacy of a Battery Toothbrush in the Reduction of Established Plaque and Gingivitis | Plaque; Gingivitis | completed | 130 |
| 2026-01-29 | P3 | Mundipharma Research Limited | NCT04368559 Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Trans | Candidemia; Mycoses; Fungal Infection; Fungemia; Invasive Candidiasis; Pneumocystis; Mold Infection; | completed | 602 |
| 2026-01-29 | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT05153317 Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older | Cystic Fibrosis | completed | 71 |
| 2026-01-29 | P3 | Inozyme Pharma | NCT06046820 The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic R | terminated | 27 |
| 2026-01-29 | P3 | Taizhou Mabtech Pharmaceutical Co.,Ltd | NCT06365879 To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | completed | 392 |
| 2026-01-29 | P2 | Sanofi SNY | NCT06454240 A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | completed | 79 |
| 2026-01-29 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06596876 A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations | Parkinson's Disease | completed | 165 |
| 2026-01-29 | P2 | RDC Clinical Pty Ltd | NCT06907680 M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis | Allergic Rhinitis Due to Grass Pollens | completed | 20 |
| 2026-01-30 | P3 | Hoffmann-La Roche | NCT04546009 A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estr | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | active not recruiting | 992 |
| 2026-01-30 | P1/P2 | COUR Pharmaceutical Development Company, Inc. | NCT05104853 Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis | Primary Biliary Cholangitis | completed | 42 |
| 2026-01-30 | P2 | Akeso | NCT05215067 A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | completed | 44 |
| 2026-01-30 | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT05516914 A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors | Malignant Tumors | completed | 98 |
| 2026-01-30 est. | P3 | Genor Biopharma Co., Ltd. | NCT05851014 A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | Breast Cancer | recruiting | 350 |
| 2026-01-30 | P3 | PolarityTE | NCT06140303 SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II) | Diabetic Foot | completed | 120 |
| 2026-01-30 | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06199037 Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients | Alzheimer's Disease | terminated | 46 |
| 2026-01-30 est. | P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06512428 A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | Advanced Esophageal Squamous Cell Carcinoma | unknown | 138 |
| 2026-01-30 | P1/P2 | Corbus Pharmaceuticals Inc. CRBP | NCT06603844 First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Solid Tumor | completed | 51 |
| 2026-01-30 est. | P1/P2 | DexTech Medical AB | NCT06616389 Study of ODX (OsteoDex) in Multiple Myeloma | Multiple Myeloma | recruiting | 12 |
| 2026-01-30 | P3 | Quince Therapeutics S.p.A. | NCT06664853 Open-Label Extension of EryDex Study IEDAT-04-2022 | Ataxia Telangiectasia | terminated | 101 |
| 2026-01-30 est. | P1/P2 | Tr1X, Inc. | NCT06721962 Treatment of Moderate to Severe Refractory Crohn's Disease | Crohns Disease | recruiting | 39 |
| 2026-01-30 | P2 | BioTissue Holdings, Inc | NCT06780306 A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03. | Dry Eye; Dry Eye Disease (DED); Dry Eye Disease With Severe Keratitis | completed | 74 |
| 2026-01-30 est. | P1/P2 | Shanghai Huaota Biopharmaceutical Co., Ltd. | NCT06895499 Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. | Hidradenitis Suppurativa | recruiting | 15 |
| 2026-01-31 | P3 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT04964284 rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC) | Differentiated Thyroid Cancer | completed | 390 |
| 2026-01-31 | P2 | GlaxoSmithKline | NCT05583344 Phase 2b Study of GSK4532990 in Adults With NASH | Nonalcoholic Fatty Liver Disease; Non-alcoholic Fatty Liver Disease | completed | 284 |
| 2026-01-31 est. | P1/P2 | Minghui Pharmaceutical Pty Ltd | NCT05652855 Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | unknown | 48 |
| 2026-01-31 est. | P3 | Sound Wave Innovation CO., LTD. SOGP | NCT05983575 A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease | Alzheimer Disease, Early Onset | active not recruiting | 220 |
| 2026-01-31 | P2 | Biologische Heilmittel Heel GmbH | NCT06278077 Neurexan - a Clinical Trial in Short-Term Insomnia Patients | Insomnia; Stress Reaction | completed | 81 |
| 2026-01-31 est. | P1/P2 | Hinova Pharmaceuticals Inc. | NCT06757335 A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer | Breast Cancer | not yet recruiting | 204 |
| 2026-01-31 est. | P2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07109700 A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin | Type 2 Diabetes | recruiting | 216 |
| 2026-01-31 est. | P3 | Tatchempharmpreparaty, JSC | NCT07167550 The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke | Stroke; Acute Stroke; Ischemic Stroke; Cerebrovascular Disorders; Physiological Effects of Drugs | recruiting | 184 |
| 2026-01-31 est. | P3 | Joincare Pharmaceutical Group Industry Co., Ltd | NCT07357051 Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Inf | Respiratory Viral Infection | recruiting | 177 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.